Summary & Overview
Other Endovascular Cardiac Valve Procedures with MCC: Inpatient Reimbursement Overview
DRG 319 encompasses other endovascular cardiac valve procedures with a Major Complication or Comorbidity and represents higher-severity catheter-based valve interventions. It matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity increases payment to reflect greater resource use and clinical complexity under Centers for Medicare & Medicaid Services rules.
DRG 319 Overview
DRG 319 covers inpatient admissions for other endovascular cardiac valve procedures when a Major Complication or Comorbidity is present. This Diagnosis-Related Group captures cases involving catheter-based interventions on cardiac valves that require higher resource use due to severe comorbid conditions or complications. It matters for Medicare payment because classification into this group increases reimbursement relative to lower-severity groups, reflecting greater expected hospital costs and care intensity. Accurate assignment affects billing, hospital revenue, and alignment with Centers for Medicare & Medicaid Services payment policy.
Clinical Trials
- Acute procedural safety and hemodynamic outcomes studies: randomized or prospective cohort studies comparing different endovascular access strategies, procedural adjuncts (for example, rapid pacing vs no pacing), or valve deployment techniques in patients undergoing non-transcatheter aortic valve replacement endovascular cardiac valve procedures with major complications. These trials enroll high-risk inpatients with complex valvular pathology, prior valve surgery, or heavily calcified annuli to measure intraprocedural complications, need for emergency conversion to open surgery, and short-term hemodynamic recovery. Findings inform perioperative protocols, resource needs (ICU use, blood product utilization) and risk adjustment that affect inpatient reimbursement and case-mix management for DRG 319.
- Comparative effectiveness and device strategy studies in high‑risk populations: observational registries or randomized comparisons examining different valve types, delivery systems, or adjunctive therapies in patients who are not candidates for standard procedures and who present with significant comorbidities or prior cardiac interventions. These studies focus on midterm outcomes such as reintervention rates, valve durability, stroke, and heart failure readmissions in complex endovascular valve recipients, helping clinicians choose approaches that optimize clinical benefit for sicker cohorts. Results guide payer coverage decisions, utilization management, and contracting around devices and implant strategies relevant to the cost profile of cases grouped to this DRG.
- Post-discharge recovery, functional outcomes, and cost-effectiveness studies: prospective cohort or pragmatic trials assessing rehabilitation pathways, heart‑failure management programs, and readmission reduction interventions for survivors of complicated endovascular valve procedures with major complications. Patient populations include older adults with multiple comorbidities who experienced prolonged hospital stays or in-hospital complications; outcomes measured include functional status, quality of life, 30–90 day readmissions, and overall episode-of-care costs. These data are critical for hospitals and payers to design discharge planning, transitional care, and bundled-payment models that reduce avoidable readmissions and align incentives for high-cost DRG 319 encounters.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.